Menu Search
Equities

FitLife Brands Inc

QO8:DEU

FitLife Brands Inc

Actions
  • Price (EUR)--
  • Today's Change--
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

FitLife Brands, Inc. is a developer and marketer proprietary nutritional supplements and wellness products for health-conscious consumers. It markets approximately 300 different products primarily online, through domestic and international GNC franchise locations as well as through more than 17,000 additional domestic retail locations. It offers NDS Nutrition, PMD Sports, SirenLabs, Core Active, Nutrology, and Metis Nutrition (together, NDS Products); iSatori, BioGenetic Laboratories, and Energize (together, the iSatori Products); Dr. Tobias, All Natural Advice, and Maritime Naturals (together, the MRC Products) and MusclePharm. Its NDS brand includes premium weight loss, sports nutrition, and general health products. Its PMD brand includes premium sports nutrition products. Its Nutrology brand included sports nutrition and general wellness products with an emphasis on natural, vegan, and organic ingredients. Its SirenLabs brand includes weight loss and sports nutrition products.

  • Revenue in USD (TTM)58.51m
  • Net income in USD7.30m
  • Incorporated2005
  • Employees37.00
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		FTLF:NAQ since
announced		Transaction
value
MusclePharm CorpDeal completed27 Sep 202327 Sep 2023Deal completed96.34%28.51m
Data delayed at least 15 minutes, as of May 24 2024 21:00 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.